Kornimate/medical-research-clean huggingface dataset:
foreign body swallows in pediatrics

Conditions: Foreign Body in Oropharynx

Summary: foreign body ingestion (fbi) is a common clinical emergency in children. most fbs smoothly pass through the digestive tract without complications; nevertheless, some fbs can cause severe morbidity and mortality. the current work aimed at evaluating how fbi can cause respiratory distress and stridor as well as their severity according to age, gender, lodgment site, and type of the object. factors influencing morbidity and mortality among studied patients will be deliberated as well.

background: foreign body ingestion (fbi) is a common clinical emergency in children. most fbs smoothly pass through the digestive tract without complications; nevertheless, some fbs can cause severe morbidity and mortality. the current work aimed at evaluating how the fbi can cause respiratory distress and stridor as well as their severity according to age, gender, lodgment site, and type of the object. factors influencing morbidity and mortality among studied patients will be deliberated as well. methods: it is a hospital-based descriptive study where all children between birth and 16 years of age who were admitted from january 1 st, 2018 to december, 31th 2021 for fbs removal were analyzed. all cases were subjected to complete history taking, physical, radiological, and bronchoscopic examination.

Eligibility criteria:
inclusion criteria: * children between birth and 16 years of age fbs removal * history suggestive of foreign body swallow exclusion criteria: - none

Keywords: foreign bodies child respiratory distress hypopharynx esophagoscopy
perioperative protective effects of lidocaine

Conditions: Elective Surgical Procedure; Colorectal Surgery

Summary: the purpose of this study is to comparing effects of intravenously (iv) administered lidocaine to effects of epidurally (ed) administered lidocaine in patients undergoing elective colorectal surgery


Eligibility criteria:
inclusion criteria: * elective colorectal surgery exclusion criteria: * asa \> 3 * history of anti-inflammatory therapy * history of inflammatory bowl diseases * history of chronic pain treatment

Keywords: systemic lidocaine peridural lidocaine perioperative analgesia inflammation anesthesia
teens-connect: preventive psycho-education for transitioning teens with diabetes

Conditions: Diabetes Mellitus, Type 1

Summary: the purpose of this study is to evaluate the use of a state-of the art internet psycho-educational program in clinical practice (teens-connect), compared to use of a standard and widely available internet diabetes program for youth (planet d™) in a mixed-method randomized clinical trial design.

the aims are: 1. to evaluate the efficacy and cost-effectiveness of provider-prescribed teens-connect (teencope™+managing diabetes) in pediatric diabetes practice compared to prescription of planet d™. the hypotheses to be studied are: 1. youth who participate in teens-connect will have better metabolic control (a1c) and quality of life (qol) than those who participate in planet d. 2. these effects will be mediated by improvements in stress/coping, self-efficacy, diabetes problem-solving, and self-management. 3. teens-connect prescribed by providers in diabetes clinics will be a cost-effective approach to reduce a1c and improve quality-adjusted life years (qalys) for youth with t1d. 2. to compare the reach, efficacy, adoption, implementation, and maintenance (re-aim) of the two provider-prescribed psycho-educational internet programs.

Eligibility criteria:
inclusion criteria: * diagnosed with type 1 diabetes for at least 6 months * age 11 to 14 years * english-speaking * assent * parent/guardian consent to participate in study exclusion criteria: \*previous exposure to teencope and/or managing diabetes

Keywords: diabetes mellitus, type 1 self care coping skills adolescent internet intervention studies chronic disease
assessment of organ failure risk predictions in icu

Conditions: Circulatory Failure; Respiratory Failure; Renal Failure

Summary: during this observational study, the investigators aim to assess the ability of icu clinicians to predict the risk of impending organ failure and retrospectively compare it to the performance of previously published machine learning models. the central hypothesis of this study is that the treating physician can predict impending organ failure in adult icu patients with similar accuracy as the best previously publishes machine learning models.

in this observational study, clinician's (physicians and nurses) assessment of the estimated imminent organ failure risk in an icu setting are prospectively collected. circulatory failure is investigated in the primary objective, and respiratory failure, renal failure, and mortality are investigated in secondary objectives. these assessments investigate the predictive performance and influencing factors for clinician prediction. the assessments will be collected in questionnaires and be performed by the clinicians directly involved in the patient treatment and by clinicians who are not actively responsible for the patient treatment. furthermore, this study aims to benchmark these risk assessments made by healthcare professionals against retrospectively generated ai risk scores for the same patients and timepoints. the ai risk scores will be calculated retrospectively from a set of models from a systematic search of the current literature. the ai models that will be employed for this analysis will be identified as indicated by a systematic review protocol and must satisfy the following two criteria: they do not require any data beyond what is routinely collected during an icu stay and may be accessed as open source. such a comparison is vital for the understanding of the relative accuracy and reliability of ai-based predictions in the context of organ failure risk compared to human performance. the data and findings from this study are anticipated to provide evidence for the clinical utility of ai-based risk scores and pave the way for future research into the optimization of ai systems for healthcare applications.

Eligibility criteria:
inclusion criteria: * patient minimum age of 18 years * emergency admission to the icu * arterial line in place exclusion criteria: * documented refusal (on the general consent form) to participate to clinical research * patients with neurologic conditions that impair the patient's level of consciousness (including, but not limited to stroke, traumatic brain injury, intracranial hemorrhage, cns infections; except polytrauma) * patients on mechanical circulatory support systems (iabp, va-ecmo, impella, vad) or extracorporeal membrane oxygenation (vv-ecmo) at any time during their icu stay; * patients receiving end-of-life care or are admitted for the sole purpose of evaluating organ donation

Keywords: machine learning intensive care artificial intelligence
blood loss between surgical blade and unipolar electrocautery in tka

Conditions: Blood Loss

Summary: using of surgical blade may have less blood loss than unipolar electrocautery in total knee arthroplasty (tka).


Eligibility criteria:
inclusion criteria: * osteoarthritis of the knee who undergoing unilateral primary total knee arthroplasty * age 50-85 years old * asa class 1-3 exclusion criteria: * unable to perform spinal anaesthesia * history of coagulation disorder * renal impairment (crcl \<30 ml/min) or cirrhosis * platelet count \< 100,000 or abnormal coagulogram * on pacemaker * stop anti-platelet or anti-coagulogram less than 7 days

Keywords: blood loss total knee arthroplasty hot knife cold knife unipolar electrocautery surgical blade
study of rns60 on pain and function after knee anterior cruciate ligament surgery

Conditions: Anterior Cruciate Ligament Reconstruction

Summary: the purpose of this study is to see if use of rns60 during acl reconstruction surgery decreases pain and improves functional capacity post-operation.


Eligibility criteria:
phase ii trial of stereotactic body radiotherapy followed by ipilimumab in treating patients with stage iv melanoma

Conditions: Recurrent Melanoma; Stage IV Skin Melanoma

Summary: this phase ii trial studies how well stereotactic body radiotherapy and ipilimumab work in treating patients with stage iv melanoma. stereotactic body radiotherapy (sbrt) may be able to send x-rays directly to the tumor and cause less damage to normal tissue. monoclonal antibodies, such as ipilimumab, target certain cells to interfere with the ability of tumor cells to grow and spread. giving sbrt with ipilimumab may kill more tumor cells.

primary objectives: i. to determine feasibility and immune-related clinical responses associated with sbrt when given in conjunction with ipilimumab. secondary objectives: i. to determine late toxicity and immune pharmacodynamic changes after sbrt followed by ipilimumab. outline: patients undergo a total of 3 fractions of stereotactic body radiotherapy between days 1-13. patients then receive ipilimumab intravenously (iv) every 3 weeks. treatment repeats every 3 weeks for 4 courses in the absence of disease progression or unacceptable toxicity. after completion of study treatment, patients are followed up within 60 days, and then every effort will be made to obtain records of patients during this follow up, and permission will be sought for the investigators and/or study team to re-contact the patient directly with regard to health status and toxicity.

Eligibility criteria:
inclusion criteria: * histologically confirmed diagnosis of melanoma * previously treated or previously untreated stage iv melanoma by american joint committee on cancer (ajcc) staging criteria * presence of an index lesion between 1 and 5 cm * eastern cooperative oncology group (ecog) performance status 0, 1, or 2 * signed informed consent document * adequate renal, hepatic, and hematologic indices for ipilimumab therapy * ability to tolerate stereotactic body radiation therapy (e.g. lie flat and hold position for treatment) exclusion criteria: * prior systemic therapy within 14 days of study enrollment; patients must be adequately recovered from prior systemic therapy side effects as deemed by the treating investigator * clinical contraindication to stereotactic body radiotherapy (e.g. active systemic sclerosis, active inflammatory bowel disease if bowel is within target field, etc) * presence of central nervous system metastasis (including active brain metastasis); active brain metastasis would be defined as untreated brain metastases; if the brain metastases have received prior treatment (usually either with surgery or radiation), they are no longer active * long-term use of systemic corticosteroids; patients with replacement steroids and not immunosuppressive steroids may enroll in the study * prior radiation therapy (rt) that precludes the delivery of sbrt
pulmonary function at high-altitude

Conditions: Pulmonary Edema

Summary: based on the findings of decreased vital capacity, decreased fev1 and increased closing volume after ascent to high altitude, some investigators suggest the presence of a subclinical high altitude pulmonary edema (hape). since these parameters are only indirect measures of pulmonary interstitial fluid accumulation, the aim of this study is to examine the effects of broncho-constriction on the increase of closing volume by extensive lung function testing in healthy mountaineers at low altitude and on the margherita hut (4559 m). as has been done in earlier studies, conventional thorax radiographs are used for verification of hape. in this study, the determination of the thoracic fluid quantity will be completed by measurements of thoracic impedance. in addition markers of pulmonary endothelial function will be assessed to get further insight into the regulation of pulmonary vascular tone at altitude and in particular into the pathophysiology of hape.


Eligibility criteria:
inclusion criteria: * mountaineering ability required for reaching the margherita hut (4559 m) exclusion criteria: * borne above 1500 m * subjects with internal medical diseases like all cardiac diseases, all pulmonary diseases, diabetes mellitus, infectious diseases, thyroid diseases, malignant diseases, hepatic or renal diseases, * (known) hypersensitivity to salbutamol or to another component of sultanol® or lidocaine, or to another component of xylocain® pump spray * intake of drugs, especially nifedipine, acetazolamide and glucocorticoids or of drugs interacting with sultanol® or xylocain® pump spray * pregnancy

Keywords: high altitude pulmonary edema pulmonary interstitial fluid pulmonary function testing hypoxia pulmonary endothelial function high altitude exposure without prior acclimatization
randomized controlled trial comparing postoperative pain following tah with ga vs. combined ga + sab

Conditions: Hysterectomy

Summary: the investigators hypothesize that a spinal anesthetic administered prior to the induction of general anesthesia will result in reduced need for pain medication and reduced postoperative pain, as well as reduced hospital stay following a total abdominal hysterectomy.


Eligibility criteria:
inclusion criteria: * american society of anesthesiologists' (asa) i and ii patients undergoing elective total abdominal hysterectomy at the saskatoon city hospital * lower transverse abdominal incision exclusion criteria: * bmi \> 40 * the tah is treatment for cancer * a history of regular opioid use * any medical condition that would make a spinal inadvisable, * an allergy or medical condition that would make it inadvisable to receive the drugs used in this study (eg. peptic ulcer disease), or * if you will also be having a salpingo-oophorectomy).
pet ct re-planning nsclc (4dct-pet)

Conditions: Lung Cancer; Non-Small Cell Lung Cancer

Summary: this study will see whether the addition of more frequent planning cts during the course of radiation, and of positron emission tomography (pet), a diagnostic test similar to ct, prior to and during a course of radiation may provide information that could potentially be used during the treatment to improve the initial radiation plan.


Eligibility criteria:
inclusion criteria: * age equal to or more than 18 years old * patients with nsclc consenting for radiotherapy to the primary tumor and / or mediastinal / hilar lymph nodes. prescription doses should be 60gy or higher. * chemo-rt patients of any stage of nsclc * patients with a measurable tumor on ct scan. * patients who are able to lie supine for two consecutive 25 minutes sessions. exclusion criteria: * trimodality patients who will have surgery within 2 months post rt * previous radiotherapy to intended treatment volumes. * patients with recurrent disease * active malignancy other than lung cancer * pregnancy * failure to provide written informed consent
irreversible electroporation(ire) for unresectable renal tumors

Conditions: Renal Tumor

Summary: the purpose of this study is to investigate the safety and efficacy of irreversible electroporation (ire) for unresectable renal tumors.

by enrolling patients with renal tumors adapted to enrolled criteria, this study will document for the first time the safety and the short and long term efficacy of percutaneous or intraoperative ire for renal tumors .

Eligibility criteria:
inclusion criteria: * unresectable kidney tumors * patients refused surgical therapy * karnofsky-index \>70% * age ≥ 18 and ≤ 80 years * life expectancy ≥ 12 month * compliance of the patient taking part in a study * informed consent exclusion criteria: * violation against one or more inclusion criteria * an estimated glomerular filtration rate (egfr) of \< 30 ml/min/1.73 m2 * qt-interval \>550 ms or cardiac arrhythmias or condition after myocardial infarction, that make an ecg-synchronisation unfeasible * active infection or severe health interference, that make taking part in a study unfeasible * pregnancy, lactation period * general contraindications for anesthesia, endotracheal anesthesia and muscle relaxation * psychiatric disorders that make taking part in a study or giving informed consent unfeasible * haemorrhage, impossible intermission of taking blood thinner, untreatable thrombophilia * thromboplastin time ≤50 %, thrombocytes ≤50 gpt/l; partial thromboplastin time \>50 * untreated urinary retention * severe hepatic dysfunction * any other clinically important renal, hematological, metabolic, neurological, gastrointestinal, hepatic or pulmonary disorders or dysfunctions preventing study participation (investigator's assessment) * taking part in another clinical study for renal tumor.

Keywords: irreversible electroporation renal tumor
a study of bgb-a445 in combination with other investigational agents in participants with non-small cell lung cancer

Conditions: Non-Small Cell Lung Cancer

Summary: the main objective of this study is to evaluate the anti-tumor activity of bgb-a445 plus investigational agents in participants with non-small cell lung cancer (nsclc)

this study will test whether bgb-a445 in combination with other agents can help treat participants with non-small cell lung cancer (nsclc) who were already treated with other anticancer agents, including anti-programmed cell death protein-1 (anti-pd-1) and anti-programmed cell death protein ligand-1 (anti-pd-l1) antibodies and platinum-based chemotherapy. the main goal of this study is to see if bgb-a445 can increase participant response to treatment, also called the overall response rate. only a portion of patients with advanced solid tumors have a durable response to currently available treatments. this represents an unmet medical need to develop improved therapeutic options. combining immunotherapies with agents having different mechanism of action might improve outcomes for these patients. this study is designed as a proof of concept to show that bgb-a445-based combination treatment may be able to improve responses and clinical benefit in patients with nsclc. stage 1 of the study will take place in china and the asia pacific region and stage 2 will be expanded to take place worldwide. the overall time to participate in this study is approximately 3 years. treatments in all cohorts will be administered up to 36 cycles (approximately 2 years) until participants experience no benefits, too many side effects, or withdraw consent.

Eligibility criteria:
inclusion criteria: * advanced or metastatic nsclc (nonsquamous or squamous) that is histologically or cytologically confirmed * participants who have received no more than 2 lines of prior systemic therapies which must include anti-programmed cell death protein ligand-1 (anti-pd-(l)1) treatment and a platinum-based chemotherapy administered in combination with, or sequentially before or after the anti-pd-(l)1 treatment * at least 1 measurable lesion as defined per recist v1.1 * eastern cooperative oncology group (ecog) performance status of 0 or 1 * adequate organ function as indicated by laboratory values during screening exclusion criteria: * with mixed small cell lung cancer * has received prior therapy targeting ox40 or any other t-cell agonists * has received prior therapy containing docetaxel and/or ramucirumab for advanced or metastatic nsclc * has received any chinese herbal medicine or chinese patent medicines used to control cancer ≤ 14 days before the first dose of study drug(s) * active leptomeningeal disease or uncontrolled and untreated brain metastasis note: other criteria may apply

Keywords: pd-l1 nsclc
safety and efficacy of softgel kovir (td0068) in the combination regimen with background treatment in covid-19 patients (kovir)

Conditions: COVID-19

Summary: the acute pneumonia pandemic caused by a new strain of corona virus 2019 named as covid-19 by the world health organization (who) is a pandemic caused by sars-cov-2 virus. the reported symptoms vary from fever or chills, cough, shortness of breath, to muscle aches, headaches, loss of taste or smell. the capsule kovir is a product based on the traditional medicine which is used to treat the cold conditions, also known as the initial plague according to the theory of traditional medicine.

the acute pneumonia pandemic caused by a new strain of corona virus 2019 named as covid-19 by the world health organization (who) is a pandemic caused by sars-cov-2 virus. the reported symptoms have included, but are not limited to fever or chills, cough, shortness of breath, muscle aches, headaches, loss of taste or smell, diarrhea, dizziness, sore throat, abdominal pain, anorexia, and vomiting. the capsule kovir is a product based on the traditional prescription which is used to treat the cold conditions, also known as the initial plague according to the theory of traditional medicine. the study timeline is expected from july 2021 to december 2022, including enrolment period, 14 days of treatment, data entry and analysis. the study compares between standard dose regimen of kovir combined with background treatment in covid-19 patients and placebo combined with background treatment in covid-19 patients. all participants will be treated and followed up in 14-day period. in case the participant meets the discharge criteria before 14 days, discontinuing the study drug will be done at the discretion of the investigators. screening procedures occur at day 1. periodic assessments are conducted daily from day 2-14. finally, end of study visit is conducted.

Eligibility criteria:
inclusion criteria: * male or female, age from 18 to 65 years old, vietnamese nationality * participants diagnosed with positive result of sars-cov-2 using real time rt-pcr test. - quantitative test results for viral load \> 4log and or ct value \< 30 respiratory fluid samples with the time of sampling within 24 hours from the time of initiation of study treatment. * voluntary participation in the study by signing an informed consent * ability to adhere to treatment according to the investigator's assessment exclusion criteria: * symptoms of severe influenza or severe acute respiratory infection (as defined by who). * acute reduction of ventilation function of respiratory apparatus and/or respiration function of the lung in any of the following three groups: * respiratory distress due to hypoxemia with pao2 less than 60mmhg when breathing room air. * respiratory distress due to hypercapnia with paco2 above 50mmhg * mixed respiratory distress accompanied by both a decrease in pao2 and an increase in paco2 * allergy/intolerance to any component of the study drug. * inability to administer medicine. * inability to comply with study procedures or to ensure compliance with study drug administration as assessed by investigators.